ATE535607T1 - Promotor - Google Patents
PromotorInfo
- Publication number
- ATE535607T1 ATE535607T1 AT08773642T AT08773642T ATE535607T1 AT E535607 T1 ATE535607 T1 AT E535607T1 AT 08773642 T AT08773642 T AT 08773642T AT 08773642 T AT08773642 T AT 08773642T AT E535607 T1 ATE535607 T1 AT E535607T1
- Authority
- AT
- Austria
- Prior art keywords
- seq
- promoter
- shortened
- nucleic acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Finger-Pressure Massage (AREA)
- Percussion Or Vibration Massage (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07012772 | 2007-06-29 | ||
| PCT/EP2008/005135 WO2009003622A1 (en) | 2007-06-29 | 2008-06-25 | Promoter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535607T1 true ATE535607T1 (de) | 2011-12-15 |
Family
ID=38476213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08773642T ATE535607T1 (de) | 2007-06-29 | 2008-06-25 | Promotor |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9080183B2 (de) |
| EP (1) | EP2164972B1 (de) |
| JP (1) | JP5108942B2 (de) |
| KR (1) | KR101183764B1 (de) |
| CN (1) | CN101688222B (de) |
| AT (1) | ATE535607T1 (de) |
| AU (1) | AU2008271658B8 (de) |
| BR (1) | BRPI0813003A2 (de) |
| CA (1) | CA2690475C (de) |
| ES (1) | ES2377765T3 (de) |
| IL (1) | IL201818A0 (de) |
| MX (1) | MX2009013120A (de) |
| RU (1) | RU2491344C2 (de) |
| TW (1) | TWI352737B (de) |
| WO (1) | WO2009003622A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130045471A1 (en) * | 2011-02-25 | 2013-02-21 | Bio-Rad Laboratories, Inc. | Training system for investigations of bioengineered proteins |
| EP2785731B1 (de) * | 2011-11-30 | 2019-02-20 | AbbVie Biotechnology Ltd | Vektoren und wirtszellen mit einem modifizierten sv40-promoter zur proteinexpression |
| JP2015502165A (ja) | 2011-12-22 | 2015-01-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 発現ベクター構成、新規の産生細胞生成法、およびポリペプチドの組換え産生のためのそれらの使用 |
| CN104011075B (zh) * | 2011-12-22 | 2017-06-06 | 弗·哈夫曼-拉罗切有限公司 | 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途 |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| EP3215191A4 (de) | 2014-11-05 | 2018-08-01 | Voyager Therapeutics, Inc. | Aadc-polynukleotide zur behandlung von morbus parkinson |
| CN107109407A (zh) | 2014-11-14 | 2017-08-29 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| EP3408397B1 (de) | 2016-01-27 | 2020-07-15 | Just-Evotec Biologics, Inc. | Hybrider promoter und verwendungen davon |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CA3024449A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| CN110214187B (zh) | 2016-05-18 | 2024-01-30 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| SG11201909868YA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| EP3618839A4 (de) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
| WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES |
| AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999062927A1 (en) * | 1998-06-05 | 1999-12-09 | Human Genome Sciences, Inc. | Connective tissue growth factor-4 |
| BRPI0411243A (pt) * | 2003-06-10 | 2006-07-11 | Nsgene As | método de produzir um polipeptìdio de neublastina biologicamente ativo, ácido nucléico, vetor de expressão, composição farmacêutica, célula, linha de células de compactação, mamìfero não-humano transgênico, dispositivo de cultura de células implantável, uso do vetor, método de tratar uma doença do sistema nervoso, e, polipetìdio de neublastina |
| JP2006050956A (ja) | 2004-08-11 | 2006-02-23 | Japan Science & Technology Agency | プルキンエ細胞における遺伝子の発現のための発現ベクター |
| US20090041783A1 (en) * | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
-
2008
- 2008-06-25 AU AU2008271658A patent/AU2008271658B8/en active Active
- 2008-06-25 AT AT08773642T patent/ATE535607T1/de active
- 2008-06-25 CN CN200880022641XA patent/CN101688222B/zh active Active
- 2008-06-25 CA CA2690475A patent/CA2690475C/en active Active
- 2008-06-25 ES ES08773642T patent/ES2377765T3/es active Active
- 2008-06-25 WO PCT/EP2008/005135 patent/WO2009003622A1/en active Application Filing
- 2008-06-25 EP EP08773642A patent/EP2164972B1/de active Active
- 2008-06-25 KR KR1020097027041A patent/KR101183764B1/ko active IP Right Grant
- 2008-06-25 MX MX2009013120A patent/MX2009013120A/es active IP Right Grant
- 2008-06-25 US US12/664,399 patent/US9080183B2/en active Active
- 2008-06-25 BR BRPI0813003-5A2A patent/BRPI0813003A2/pt not_active Application Discontinuation
- 2008-06-25 RU RU2010102812/10A patent/RU2491344C2/ru active
- 2008-06-25 JP JP2010513746A patent/JP5108942B2/ja active Active
- 2008-06-27 TW TW097124386A patent/TWI352737B/zh active
-
2009
- 2009-10-29 IL IL201818A patent/IL201818A0/en active IP Right Grant
-
2015
- 2015-05-26 US US14/721,061 patent/US9926567B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9080183B2 (en) | 2015-07-14 |
| EP2164972A1 (de) | 2010-03-24 |
| ES2377765T3 (es) | 2012-03-30 |
| KR101183764B1 (ko) | 2012-09-17 |
| RU2010102812A (ru) | 2011-08-10 |
| RU2491344C2 (ru) | 2013-08-27 |
| AU2008271658B2 (en) | 2013-06-06 |
| US20160083735A1 (en) | 2016-03-24 |
| CN101688222A (zh) | 2010-03-31 |
| JP2010531647A (ja) | 2010-09-30 |
| TW200914612A (en) | 2009-04-01 |
| AU2008271658B8 (en) | 2013-07-04 |
| EP2164972B1 (de) | 2011-11-30 |
| CA2690475A1 (en) | 2009-01-08 |
| CN101688222B (zh) | 2013-03-06 |
| KR20100024438A (ko) | 2010-03-05 |
| WO2009003622A1 (en) | 2009-01-08 |
| US9926567B2 (en) | 2018-03-27 |
| BRPI0813003A2 (pt) | 2014-10-14 |
| US20100159489A1 (en) | 2010-06-24 |
| WO2009003622A8 (en) | 2009-11-05 |
| MX2009013120A (es) | 2010-01-15 |
| JP5108942B2 (ja) | 2012-12-26 |
| TWI352737B (en) | 2011-11-21 |
| CA2690475C (en) | 2014-07-29 |
| AU2008271658A8 (en) | 2013-07-04 |
| IL201818A0 (en) | 2011-08-01 |
| AU2008271658A1 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE535607T1 (de) | Promotor | |
| PH12018501250A1 (en) | Chimeric factor viii polypeptides and uses thereof | |
| IN2012DN05169A (de) | ||
| UY39963A (es) | Composiciones herbicidas a base de carbamoíltriazolinona y métodos de uso | |
| CR11504A (es) | Deteccion mejorada de la expresion de mage-a | |
| BR112014019901A2 (pt) | proteínas de fator viii recombinante | |
| GB201009493D0 (en) | Modified recombinant factor viii and von willebrand factor and methods of use | |
| MX2009007001A (es) | Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos. | |
| ES2531135T3 (es) | Fitasas, ácidos nucleicos que las codifican y métodos para su producción y uso | |
| ES2676499T3 (es) | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones | |
| MX2010001856A (es) | Proteina. | |
| BRPI0517493A (pt) | polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo | |
| MY160995A (en) | Polypeptides with permease activity | |
| WO2010129895A3 (en) | Cd133 epitopes | |
| NZ600205A (en) | Selective exosite inhibition of papp-a activity against igfbp-4 | |
| EA202190240A1 (ru) | Варианты рекомбинантного белка | |
| UA108778C2 (xx) | Протираковий злитий протеїн | |
| MX2017010359A (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). | |
| MX2018008293A (es) | Factor de von willebrand mutado. | |
| UA107596C2 (uk) | Виділений поліпептид, який зв'язується з рецептором інсуліноподібного фактора росту 1 | |
| DE602005020339D1 (de) | Pntr transkriptionsfaktor knock-out und dessen verwendungen | |
| EA202090167A1 (ru) | Армированная длинным углеродным волокном полипропиленовая композиция | |
| CY1116486T1 (el) | Βελτιωμενο συστημα εκφρασης ανθρωπινης μακρας πεντραξινης 3 και χρησεις αυτης | |
| ATE549351T1 (de) | Chimärer peptidantagonist für gpcr135 oder gpcr142 | |
| WO2020020687A3 (en) | Heterorhabditis bacteriophora with enhanced shelf-life |